EVOLUS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
EVOLUS, INC. (EOLS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$1.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-05
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$1.25M, a 131.94% decline year-over-year.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $14.00K.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $4.51M.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $107.00K.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $6.38M.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$7.18M.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$4.26M.
- EVOLUS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$5.75M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.25M 10-Q · filed 2026-08-05 | -$1.24M 10-Q · filed 2026-08-05 | $3.27M derived: sum of 3 quarters · filed 2026-08-05 | $3.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.00K 10-Q · filed 2026-05-04 | $4.53M derived: sum of 2 quarters · filed 2026-05-04 | $4.63M derived: sum of 3 quarters · filed 2026-05-04 | $8.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.62M derived: sum of 2 quarters · filed 2026-03-03 | $8.53M derived: sum of 3 quarters · filed 2026-08-05 | $6.38M 10-K · filed 2026-03-03 |
| 2025-09-30 | $107.00K 10-Q · filed 2025-11-05 | $4.02M derived: sum of 2 quarters · filed 2026-08-05 | $1.87M 10-Q · filed 2025-11-05 | $305.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.91M 10-Q · filed 2026-08-05 | $1.76M 10-Q · filed 2026-08-05 | $198.00K derived: sum of 3 quarters · filed 2026-08-05 | -$2.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.15M 10-Q · filed 2026-05-04 | -$3.72M derived: sum of 2 quarters · filed 2026-05-04 | -$6.14M derived: sum of 3 quarters · filed 2026-05-04 | -$7.75M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.99M derived: sum of 2 quarters · filed 2026-03-03 | -$5.60M derived: sum of 3 quarters · filed 2026-03-03 | -$7.18M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$2.43M 10-Q · filed 2025-11-05 | -$4.03M derived: sum of 2 quarters · filed 2025-11-05 | -$5.61M 10-Q · filed 2025-11-05 | -$4.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$1.60M 10-Q · filed 2025-08-05 | -$3.18M 10-Q · filed 2025-08-05 | -$2.31M derived: sum of 3 quarters · filed 2026-03-03 | -$4.11M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$1.58M 10-Q · filed 2025-05-07 | -$703.00K derived: sum of 2 quarters · filed 2026-03-03 | -$2.50M derived: sum of 3 quarters · filed 2026-03-03 | -$4.19M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $875.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$927.00K derived: sum of 2 quarters · filed 2026-03-03 | -$2.61M derived: sum of 3 quarters · filed 2026-03-03 | -$4.26M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$1.80M 10-Q · filed 2024-11-06 | -$3.48M derived: sum of 2 quarters · filed 2024-11-06 | -$5.13M 10-Q · filed 2024-11-06 | -$6.94M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | -$1.68M 10-Q · filed 2024-07-31 | -$3.33M 10-Q · filed 2024-07-31 | -$5.14M derived: sum of 3 quarters · filed 2025-03-04 | -$6.36M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$1.65M 10-Q · filed 2024-05-07 | -$3.46M derived: sum of 2 quarters · filed 2025-03-04 | -$4.67M derived: sum of 3 quarters · filed 2025-03-04 | -$6.09M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$3.02M derived: sum of 2 quarters · filed 2025-03-04 | -$4.44M derived: sum of 3 quarters · filed 2025-03-04 | -$5.75M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$1.22M 10-Q · filed 2023-11-07 | -$2.63M derived: sum of 2 quarters · filed 2023-11-07 | -$3.95M 10-Q · filed 2023-11-07 | -$6.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$1.41M 10-Q · filed 2023-08-02 | -$2.73M 10-Q · filed 2023-08-02 | -$4.97M derived: sum of 3 quarters · filed 2023-08-02 | -$6.37M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | -$1.32M 10-Q · filed 2023-05-09 | -$3.56M derived: sum of 2 quarters · filed 2023-05-09 | -$4.96M derived: sum of 3 quarters · filed 2023-05-09 | -$6.34M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$3.64M derived: sum of 2 quarters · filed 2023-03-08 | -$5.02M derived: sum of 3 quarters · filed 2023-03-08 | -$6.29M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$1.40M 10-Q · filed 2022-11-08 | -$2.78M derived: sum of 2 quarters · filed 2022-11-08 | -$4.05M 10-Q · filed 2022-11-08 | -$2.04M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$1.38M 10-Q · filed 2022-08-02 | -$2.65M 10-Q · filed 2022-08-02 | -$642.00K derived: sum of 3 quarters · filed 2022-08-02 | $1.83M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$1.27M 10-Q · filed 2022-05-10 | $739.00K derived: sum of 2 quarters · filed 2022-05-10 | $3.21M derived: sum of 3 quarters · filed 2022-05-10 | $777.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.01M 10-K · filed 2021-03-25 | $4.48M derived: sum of 2 quarters · filed 2021-11-02 | $2.04M derived: sum of 3 quarters · filed 2021-11-02 | $2.01M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.47M 10-Q · filed 2021-11-02 | $38.00K derived: sum of 2 quarters · filed 2021-11-02 | $9.92M 10-Q · filed 2021-11-02 | $13.74M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | -$2.43M 10-Q · filed 2021-08-04 | $7.45M 10-Q · filed 2021-08-04 | $11.27M derived: sum of 3 quarters · filed 2021-08-04 | $9.47M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $9.88M 10-Q · filed 2021-05-12 | $13.70M derived: sum of 2 quarters · filed 2021-05-12 | $11.91M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $2.02M derived: sum of 2 quarters · filed 2021-03-25 | -$4.16M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$1.79M 10-Q · filed 2020-10-29 | -$7.98M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |